Dermatology

A new patient decision aid uses a staged approach to help adults with moderate to severe atopic dermatitis choose systemic treatments effectively.

Maui Derm 2026 showcased groundbreaking advancements in dermatology, focusing on biologics, innovative treatments, and future technologies for skin health.

These findings suggest the mental health burden in nonmelanoma skin cancer reflects broader social and clinical factors rather than disease-specific effects.

Discover how innovations in biology and engineering are transforming dermatology, featuring breakthroughs in laser therapies and precision medicine.

Vivian Shi, MD, discusses the evolving strategies for managing hidradenitis suppurativa, including biologics and combination therapies, at Maui Derm 2026.

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

LLMs provide valuable answers to common Mohs surgery questions, supporting postoperative care and patient education without replacing physician guidance.

Experts discuss groundbreaking therapies in dermatology at Maui Derm 2026, addressing complex skin diseases and enhancing patient care with innovative treatments.

Daniel Siegel, MD, discusses a loophole he looks out for in ICD-10 coding and billing.

Maui Derm 2026 showcases groundbreaking clinical trial data and innovative strategies in dermatology.

Patients with proinflammatory, pro-oxidative diets may face accelerated biological aging and increased skin cancer risk.

On average, patients with multiple prior dermatology visits still scored below 75% when identifying common skin cancer terms, underscoring the need for clearer patient-physician communication.

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Phase 3 ADORING data show tapinarof cream delivers early, consistent skin, itch, and sleep improvements in children with atopic dermatitis, with low adverse event rates.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.